|
[1]
|
Iron Responsiveness to Lysosomal Disruption: A Novel Pathway to Alzheimer’s Disease
Journal of Alzheimer's Disease,
2023
DOI:10.3233/JAD-230953
|
|
|
|
|
[2]
|
Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis
Journal of Neural Transmission,
2020
DOI:10.1007/s00702-019-02138-1
|
|
|
|
|
[3]
|
Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials
Expert Opinion on Emerging Drugs,
2020
DOI:10.1080/14728214.2020.1769067
|
|
|
|
|
[4]
|
Iron-responsive-like elements and neurodegenerative ferroptosis
Learning & Memory,
2020
DOI:10.1101/lm.052282.120
|
|
|
|
|
[5]
|
The roles of iron and HFE genotype in neurological diseases
Molecular Aspects of Medicine,
2020
DOI:10.1016/j.mam.2020.100867
|
|
|
|
|
[6]
|
Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity
International Journal of Molecular Sciences,
2019
DOI:10.3390/ijms20040994
|
|
|
|
|
[7]
|
Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity
International Journal of Molecular Sciences,
2019
DOI:10.3390/ijms20040994
|
|
|
|
|
[8]
|
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
Antioxidants & Redox Signaling,
2018
DOI:10.1089/ars.2017.7493
|
|
|
|
|
[9]
|
Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer’s disease
Pharmacological Research,
2017
DOI:10.1016/j.phrs.2017.11.028
|
|
|
|